About mereo biopharma group plc - MREO
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
MREO At a Glance
Mereo BioPharma Group Plc
1 Cavendish Place
London, Greater London W1G 0QF
| Phone | 44-333-023-7300 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -43,271,200.38 | |
| Sector | Health Technology | Employees | 36 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MREO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.906 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -9.814 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.014 |
MREO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,201,977.788 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MREO Liquidity
| Current Ratio | 5.399 |
| Quick Ratio | 5.399 |
| Cash Ratio | 5.041 |
MREO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -60.566 |
| Return on Equity | -77.612 |
| Return on Total Capital | -64.202 |
| Return on Invested Capital | -73.972 |
MREO Capital Structure
| Total Debt to Total Equity | 10.545 |
| Total Debt to Total Capital | 9.539 |
| Total Debt to Total Assets | 8.416 |
| Long-Term Debt to Equity | 0.307 |
| Long-Term Debt to Total Capital | 0.277 |